GSK (NYSE:GSK – Get Free Report) and Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
15.7% of GSK shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares GSK and Kyverna Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GSK | $32.67 billion | 3.19 | $7.54 billion | $3.70 | 13.90 |
| Kyverna Therapeutics | N/A | N/A | -$161.31 million | ($3.65) | -2.30 |
GSK has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
GSK has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for GSK and Kyverna Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GSK | 3 | 6 | 1 | 0 | 1.80 |
| Kyverna Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
GSK presently has a consensus price target of $53.00, indicating a potential upside of 3.08%. Kyverna Therapeutics has a consensus price target of $28.67, indicating a potential upside of 241.27%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than GSK.
Profitability
This table compares GSK and Kyverna Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GSK | 17.47% | 46.75% | 11.53% |
| Kyverna Therapeutics | N/A | -81.47% | -66.70% |
Summary
GSK beats Kyverna Therapeutics on 7 of the 13 factors compared between the two stocks.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
